CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Decision Follows Robust Stakeholder Input and Creates Pathway for Enhanced Access and Coverage of Drugs that Receive Traditional FDA Approval Treatment for Alzheimer’s Disease Today, the Centers for Medicare & Medicaid Services (CMS) released a national policy for […]
As of April 5, 2022, the U.S. Food and Drug Administration (FDA) reissued the emergency use authorization (EUA) for GSK-Vir Biotechnology’s sotrovimab monoclonal antibody treatment. It is important to note Sotrovimab is no longer authorized for use within the U. S. The full FDA press release can be read at FDA updates Sotrovimab emergency use […]
“Moral injury has been defined as the “psychological, biological, spiritual, behavioral and social impact of perpetrating, failing to prevent, or bearing witness to acts that transgress deeply held moral beliefs and expectations.”1 Since this definition was introduced in 2009, the subsequent decade of research focused almost exclusively on military veterans. Among military personnel, the killing of […]
Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals
FDA Authorizes Second COVID Booster
OSHA COVID-19 Focused Inspections Initiative coming to healthcare facilities.
FDA currently reviewing the ability of VESTEX® to reduce COVID-19. While the FDA has not yet reviewed the ability of products protected by VESTEX® to reduce COVID-19, preliminary research has documented results equal to or better than the reduction of MRSA. This research is being assessed analytically and VESTEX® does intend to seek FDA clearance for specific claims […]